Detalhe da pesquisa
1.
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Nature
; 579(7798): 274-278, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103181
2.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290461
3.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 400(10358): 1103-1116, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099926
4.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31079938
5.
Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.
Br J Pharmacol
; 181(13): 2033-2052, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486310
6.
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
J Clin Oncol
; : JCO2302166, 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38552197
7.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
J Transl Med
; 11: 76, 2013 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-23522020
8.
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med
; 4(1): 100878, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36599350
9.
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
JAMA Oncol
; 8(2): 275-280, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940781
10.
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(16): 3452-3463, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35699599
11.
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
Eur Urol
; 79(5): 659-662, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654802
12.
Molecular determinants of response to PD-L1 blockade across tumor types.
Nat Commun
; 12(1): 3969, 2021 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172722
13.
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Eur Urol
; 79(5): 665-673, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33678522
14.
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Cancer Cell
; 38(6): 803-817.e4, 2020 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33157048
15.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 26(5): 693-698, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32405063
16.
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clin Cancer Res
; 14(9): 2775-84, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18451245
17.
CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
PLoS One
; 13(1): e0190158, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29320521
18.
Phase I study of the anti-α5ß1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 82(2): 339-351, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905898
19.
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(12): 1941, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291359
20.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(6): 749-757, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867230